Ideaya Biosciences Inc reported a decline in its share price in after-hours trading, with the stock down 7.9% following the company's disclosure that it plans to pursue a public offering totaling $300 million. The offering will include sales of common stock and, for certain investors, pre-funded warrants exercisable for common stock, structured as an underwritten public offering.
The market response in after-hours sessions reflected investor concern about the possibility of dilution should the equity and warrant sale proceed. The company noted that it intends to grant the underwriters a 30-day option to buy up to an additional $45 million of common stock, expanding the potential proceeds from the transaction should that option be exercised.
Ideaya cautioned that the proposed transaction remains subject to market and other conditions and that there can be no assurance regarding whether it will be completed or what the final terms will be if it is completed. Those caveats were included in the company's description of the offering process.
J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are listed as joint book-running managers for the potential offering.
Ideaya Biosciences is a precision medicine oncology company that focuses on discovering, developing, and commercializing targeted therapies for cancer. The firm combines small-molecule drug discovery, structural biology, and bioinformatics in order to create therapies matched to genetic drivers of disease. Its development pipeline emphasizes synthetic lethality approaches and antibody-drug conjugates directed at molecularly defined solid tumor indications.
The company's public disclosure frames the financing as subject to uncertainty, and the immediate price movement in after-hours trading illustrates a common market reaction when issuers announce potential new equity issuances. The company did not provide additional details about timing, pricing, or specific investors in the announcement.